“Real world survey” of hydrogen-controlled cancer: a follow-up report of 82 advanced cancer patients.
Ji-Bing Chen, Xiao-Feng Kong, You-Yong Lv, Shu-Cun Qin, Xue-Jun Sun, Feng Mu, Tian-Yu Lu, Ke-Cheng Xu · Medical gas research · 2019
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 82 patients with stage III and IV cancer, of the 58 cases with one or more abnormal tumor markers elevated, the markers were decreased at 13-45 days (median 23 days) after hydrogen inhalation in 36.2%. 20 reported that neutral pH hydrogen-enriched electrolytic water inhibited the colony formation efficiency and colony size of human HSC-4 tongue cancer cells while having no significant inhibitory effect on normal tongue epithelioid cells and also inhibited the growth and migration ability of human HT-1080 fibrosarcoma cells. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 82 patients with stage III and IV cancer. Of the 58 cases with one or more abnormal tumor markers elevated, the markers were decreased at 13-45 days (median 23 days) after hydrogen inhalation in 36.2%. 20 reported that neutral pH hydrogen-enriched electrolytic water inhibited the colony formation efficiency and colony size of human HSC-4 tongue cancer cells while having no significant inhibitory effect on normal tongue epithelioid cells and also inhibited the growth and migration ability of human HT-1080 fibrosarcoma cells.
What the Researchers Studied
The researchers studied 82 patients with stage III and IV cancer. The study used a human clinical study. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 66.7% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 66.7% source-reported H₂ gas concentration; 3000 mL/min total gas flow (approximately 2001 mL/min H₂ component). Of the 58 cases with one or more abnormal tumor markers elevated, the markers were decreased at 13-45 days (median 23 days) after hydrogen inhalation in 36.2%. 20 reported that neutral pH hydrogen-enriched electrolytic water inhibited the colony formation efficiency and colony size of human HSC-4 tongue cancer cells while having no significant inhibitory effect on normal tongue epithelioid cells and also inhibited the growth and migration ability of human HT-1080 fibrosarcoma cells. Hydrogen exerts antioxidant and anti-inflammatory effects that may be exploited to control cancer, the occurrence and progression of which is closely related to peroxidation and inflammation.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 82 patients with stage III and IV cancer. The reported sample size was 82. The study used a human clinical study. The source-reported hydrogen concentration was 66.7% source-reported H₂ gas concentration.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.